Q2 EPS Forecast for CytomX Therapeutics Reduced by Analyst

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of CytomX Therapeutics in a report issued on Thursday, May 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at ($0.02) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $50.92 million for the quarter, compared to the consensus estimate of $35.42 million. During the same quarter in the prior year, the firm earned $0.17 earnings per share.

CTMX has been the subject of several other reports. Piper Sandler raised their price objective on CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a research note on Thursday, May 15th. Wedbush restated an “outperform” rating and issued a $6.00 price target (up from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Finally, StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th.

CytomX Therapeutics Trading Down 3.3%

CTMX opened at $2.06 on Monday. The stock has a 50-day moving average of $0.88 and a 200 day moving average of $0.91. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $2.55. The firm has a market cap of $166.08 million, a P/E ratio of 12.12 and a beta of 1.11.

Institutional Trading of CytomX Therapeutics

Several institutional investors have recently added to or reduced their stakes in CTMX. Miller Financial Services LLC bought a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $26,000. Traphagen Investment Advisors LLC purchased a new position in CytomX Therapeutics during the 4th quarter valued at $31,000. Algert Global LLC bought a new position in CytomX Therapeutics in the 4th quarter valued at $35,000. Velan Capital Investment Management LP bought a new position in CytomX Therapeutics in the 4th quarter valued at $36,000. Finally, Aspire Growth Partners LLC purchased a new stake in CytomX Therapeutics in the fourth quarter worth $42,000. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.